{"ticker": {"uuid": "d81ef978-4e15-4f4e-93be-4a1e52989256", "symbol": "IMRN", "name": "Immuron Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPXzBFUW03Sm9pS2YzLWVUeGNRbWR0OEp0Szd6aFZHR2tpWEo5WTlDaEFIUWVzcWkxUGRMYW1SYWV4b1NpRDBnbTVUakFPcFA3QkxONDBENkk5aE52QVlpQlJ4V3czV0s4SDY5TnVfM0VMNGtZMVVZZjhobGg3SUJpS0kzZDJqYW1oZE5JbUFDU3dRdE9kdUhKTEg5MTJWRUg0WnExdEN2T2ZnR2FqdEoxZThraHN1VjVEeXJBTzUwOA?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T15:07:01+00:00", "published_display": "16 Jul 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Reports FY26 Global Sales Up 6% on Strong Travelan Growth in Australia and the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQeEpSVXdrOWdyd3dyVjRQVmhKRzg0R2tyM1NRcHhmOHR2czFVc3JJVWNyRnQ3ZnRjMnkxcnVUV09COEh4Sl9nWUhTVWFvNkJlWDdSMWxPa2tVRkRTM1B4dDVacEFGajlual92NkJITVd0ckJ0ZXhmNEFkdV9aTktibU5taDVqNzVkb2xHU1NxQjY1STlJYnhIN1FRdnZQRjFnb0FHZ09IQTJvR29XWHhBN2htLUhENGhFMkVyS29TMFlVd21T?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T10:11:00+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immuron-fy26-sales-four-consecutive-100000318.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron's Travelan Sales Grow for Four Straight Quarters", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPZDlzUF9pa3kxLXkwMmFsVE9jSVgzcTVPN0lQcXc5UmNtbkR3MExMX0NQRDZfLTAxdmtSaU14VVdHenZLTXkxVUlpd2pIUVRhWjVzM3o4SzhOZ3hFbkNObUNkbDh4RTEtMDdPSDZRdUYwOXpxUG1SRW9MVVhrOGR3NFV6U2J2cV9YS2FlYzNWNGx5VUJ4eG8zV055ZldvZ1kwMkxVRi03cFJzc1JXeE1Id2dHbjV1SGtpNC1FSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia's Immuron sales reach $7.7 million in FY26", "summary": "Immuron (ASX:IMC) announced global sales of $7.7 million for FY26, marking a 6% increase over the previous year. This growth was primarily driven by strong sales of Travelan in Australia and steady expansion in North America. Despite the positive sales figures, the Immuron share ", "url": "https://grafa.com/en/news/australia/immuron-sales-reach-7-7-million-in-fy26", "source_name": "grafa.com", "published_at": "2026-07-16T02:30:00", "published_display": "16 Jul 2026 02:30", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuron Seeking Partner to Advance IMM-529 in Clostridioides Difficile Infection", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immuron-seeking-partner-advance-imm-110149084.html", "source_name": "MT Newswires", "published_at": "2026-07-06T11:01:49+00:00", "published_display": "06 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push", "summary": "Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for its IMM-529 program, which targets Clostridioides difficile infection (CDI). IMM-529 has FDA Investigational New Drug approval for a planned Phase 2 trial in Australia, with a projected base case ", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-4f81c9b388b4.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:40:42", "published_display": "06 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy", "summary": "Immuron Limited has engaged Pullan Consulting to strategically advance its investigational drug, IMM-529, designed to treat Clostridioides difficile infection (CDI). This move follows the FDA's approval of IMM-529's Investigational New Drug (IND) application, allowing for upcomin", "url": "https://kalkine.com.au/news/announcements/immuron-engages-pullan-consulting-to-advance-imm-529-partnering-strategy", "source_name": "Kalkine", "published_at": "2026-07-06T10:53:00", "published_display": "06 Jul 2026 10:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy", "summary": "Immuron Limited has engaged Pullan Consulting to advance its partnering strategy for IMM-529, a treatment for Clostridioides difficile infection (CDI). The company has FDA approval for its IMM-529 Investigational New Drug application and is seeking a partner to fund clinical deve", "url": "https://markets.businessinsider.com/news/stocks/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-1036299126", "source_name": "markets.businessinsider.com", "published_at": "2026-07-06T10:40:42", "published_display": "06 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron seeks partner for gut infection drug IMM-529", "summary": "Immuron (NASDAQ: IMRN, ASX: IMC) has engaged Pullan Consulting to find a strategic partner for IMM-529, its oral polyclonal antibody candidate for Clostridioides difficile infection (CDI). IMM-529 has FDA-cleared IND 32095 and is Phase 2 trial-ready, with a planned randomized, do", "url": "https://www.stocktitan.net/news/IMRN/immuron-advances-imm-529-clostridioides-difficile-infection-xhzmrjcwvm6o.html", "source_name": "Stock Titan", "published_at": "2026-07-06T09:40:42", "published_display": "06 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) Edges Higher Amid Low-Volume Trading; Potential Consolidation Near Support - ADD Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNZ0xzM0QwQlFCOHpzM1ZuNjFIRnk4bnFtdTNiMDJEU0M1WVFJLUtpcTQtb0ZoNmQ4SlBWNmZtWEhUeWt2NzZSS2hpVkZSSEQySGIzVi02LU9aWmZPVVZMTjlPZllQclIteGRVM21BVWJSTDBlWmt6NEVoUVJlUUlycDRuTGtyQ2pmRGlmc0tjRXpUVHdlNDRZVUQ1cHZRUDg3SmZzU3ZzSzlObTlUNDZBemREVF9wSHd6TzZQM0VIamNESlk5Z3NjcQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T02:31:45+00:00", "published_display": "06 Jul 2026 02:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue", "summary": "Immuron Limited (NASDAQ: IMRN) has announced a change in its issued capital, with 3,805,528 ordinary fully paid shares ceasing on the ASX. Following this cessation, the company now has 322,848,081 ordinary shares on issue. This adjustment to the share count will be used by the AS", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-8e2006592d7c.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:59:39", "published_display": "29 Jun 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Cancels 3.8 Million Shares at $0.032 Each Under Unmarketable Parcel Buy-Back", "summary": "Immuron Limited (ASX: IMC) has completed the cancellation of 3,805,528 ordinary fully paid shares at AUD $0.032 each as part of an unmarketable parcel buy-back program, effective June 29, 2026. This move reduces the company's total quoted ordinary share count to 322,848,081 and a", "url": "https://kalkine.com.au/news/announcements/immuron-cancels-38-million-shares-at-0032-each-under-unmarketable-parcel-buy-back", "source_name": "Kalkine", "published_at": "2026-06-29T02:41:39", "published_display": "29 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Immuron Ltd ADR For: 23 June By Investing.com", "summary": "This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23rd. The content itself is very brief, consisting only of the headline repeated several times, and primarily serves as an entry point to Investing.com's broader financial news and market data platform, wit", "url": "https://in.investing.com/news/stock-market-news/form-6k-immuron-ltd-adr-for-23-june-93CH-5465962", "source_name": "Investing.com India", "published_at": "2026-06-27T04:40:44", "published_display": "27 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Immuron Ltd ADR For: 23 June", "summary": "This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23. It also includes standard disclaimers about the risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility and potential loss of investment. The content stresse", "url": "https://m.uk.investing.com/news/stock-market-news/form-6k-immuron-ltd-adr-for-23-june-93CH-4739689?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T13:10:43", "published_display": "23 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back", "summary": "Immuron Limited has completed a small holding share sale facility, buying back 3,805,528 ordinary shares at $0.032 per share, totaling $121,777. These shares will be cancelled, reducing the company's total shares on issue from 326,653,609 to 322,848,081 and decreasing the number ", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-4c342aaa3c33.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:39:57", "published_display": "22 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital", "summary": "Immuron Limited announced the expiry of 1.43 million IMCAI options listed on the ASX, which ceased on June 18, 2026, without being exercised or converted, and with no consideration paid. Following this, the company updated its issued capital to 326,653,609 ordinary fully paid sha", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-6b8b572858f1.html", "source_name": "Stock Titan", "published_at": "2026-06-19T21:40:54", "published_display": "19 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Immuron Ltd (IMRN). It lists specific institutional shareholders, their shareholdings, and the percentage change in their positions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:23", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Immuron Ltd (IMRN), detailing support and resistance levels, and analyzing various technical indicators and moving averages. As of the report, IMRN's technical indicators present a mixed signal with 1 buy and 2 sell signals, while mov", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:43", "published_display": "17 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Immuron Ltd (IMRN), highlighting that one analyst rates the stock as a \"Buy\" with a target price of USD 5.00, representing a potential upside of 257.14%. The company's current stock price is 1.040 USD, with a market cap of 7.56M. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T07:40:59", "published_display": "17 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immuron Ltd (IMRN)'s dividend and stock split history. It indicates that no dividends have been distributed in the past five years and there is no data available for past stock splits. The page serves as a data placeholder for these financial ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T05:11:30", "published_display": "17 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Immuron Ltd (IMRN), listing its major shareholders and institutional holdings as of recent reporting periods. Key institutional investors include Morgan Stanley, Citadel Advisors, and XTX Markets, with updated statistics on shares", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T05:11:29", "published_display": "17 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Immuron Ltd (IMRN) as of July 6, 2023, showcasing its performance across different business segments and geographical regions. It highlights that the Travelan segment accounts for the vast majority of its revenue at 96.68%, w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T04:11:29", "published_display": "17 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (ASX: IMC): Advancing Gastrointestinal Product Portfolio Across Multiple Markets", "summary": "Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is actively expanding its gastrointestinal product portfolio and market presence, focusing on digestive health with products like Travelan\u00ae for travellers' diarrhoea and ProIBS\u00ae for IBS symptoms. The company reported a 16% increase in globa", "url": "https://kalkinemedia.com/au/news/featured-news/immuron-asx-imc-advancing-gastrointestinal-product-portfolio-across-multiple-markets", "source_name": "Kalkine Media", "published_at": "2026-06-02T04:09:38", "published_display": "02 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRN - Immuron Limited ADR Stock Price and Quote", "summary": "This article provides a detailed stock quote and company information for Immuron Limited (IMRN), an Australian biopharmaceutical company. It includes financial data, performance metrics, key ratios, and a comprehensive list of recent company news and events. The company focuses o", "url": "https://finviz.com/stock?t=IMRN", "source_name": "Finviz", "published_at": "2026-05-30T13:12:29", "published_display": "30 May 2026 13:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) responds to ASX query on share price", "summary": "Immuron Limited has filed a Form 6-K in response to an ASX price query regarding recent trading activity in its shares. The company stated it is not aware of any undisclosed information that would explain the movements and confirmed its compliance with ASX Listing Rule 3.1 on con", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-4890cba04b2e.html", "source_name": "Stock Titan", "published_at": "2026-05-28T12:08:59", "published_display": "28 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRN Technical Analysis | Trend, Signals & Chart Patterns | IMMURON LTD-SPON ADR (NASDAQ:IMRN)", "summary": "IMMURON LTD-SPON ADR (IMRN) has a strong technical rating of 8 out of 10, showing positive short-term trends and outperforming 85% of all stocks in the past year. However, its setup rating is low at 1 due to extended recent price rises, suggesting a wait for consolidation before ", "url": "https://www.chartmill.com/stock/quote/IMRN/technical-analysis", "source_name": "ChartMill", "published_at": "2026-05-27T11:39:03", "published_display": "27 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00", "summary": "Emerging Growth Research has released a Flash Report on Immuron (Nasdaq: IMRN), reaffirming its Buy-Extended rating and elevating its 12-month price target from $3.90 to $4.00. This increase reflects Immuron's continued revenue growth, expanding commercial presence, and advanceme", "url": "https://www.moomoo.com/news/post/68690949/emerging-growth-research-releases-flash-report-on-immuron-maintains-buy", "source_name": "Moomoo", "published_at": "2026-05-23T10:40:17", "published_display": "23 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3", "summary": "Immuron Ltd Chief Commercial Officer Flavio Palumbo has filed an initial ownership report (Form 3) disclosing his equity interests in the company. The filing indicates he directly holds 1,142,909 Ordinary Shares and 640,824 Performance Rights. These Performance Rights have a zero", "url": "https://www.stocktitan.net/sec-filings/IMRN/form-3-immuron-ltd-initial-statement-of-beneficial-ownership-7272ca8cfdf2.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:10:11", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) director discloses shareholdings and long-dated options", "summary": "Immuron Ltd director Daniel Jude Pollock has filed an initial Form 3, disclosing his direct ownership of 568,750 Ordinary Shares and indirect ownership of 174,480 Ordinary Shares through joint ownership with his spouse. The filing also reveals his holdings of options over 1,000,0", "url": "https://www.stocktitan.net/sec-filings/IMRN/form-3-immuron-ltd-initial-statement-of-beneficial-ownership-74f4d58890a1.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:10:11", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuron Ltd IMRN", "summary": "This page provides an overview of Immuron Ltd (IMRN) stock, showing its current trading price, market capitalization, and recent performance. The stock is trading at $0.880, up 9.86%, with a market cap of $5.15M. The page includes sections for financials, discussions, and analysi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/comments", "source_name": "TradingKey", "published_at": "2026-05-13T08:39:17", "published_display": "13 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuron (IMRN) Sees Impressive Sales Surge for Travelan in FY25", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQbjMxZEVCbnltUFhvUEtmd2g1RkUtaEpPaktVWTFkUXJoXy03SWdrcUVJOTdWZDJWcVNWbTdCMXA5bTAyanMzTWxIemNzX3d6R2NBRndNRUVqSWtBVWZaOG5obTBXd0E5RU5pajdTeU1iMHhHcGxJN1gyM0FqUU83azZvWXJURFktVkVJYzlVNHFqMUhQUlZZeTVZd2VNdXNiNXg2dDFqakIwbl85anJtc1dhRTZpNnBRMGkyaTlVVXNiZ0JNTFhj?oc=5", "source_name": "GuruFocus", "published_at": "2025-07-17T07:00:00+00:00", "published_display": "17 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5VQkRiNXRSbmkyTkVWQzNsbjJuQkhlOFBfWkt5RHR5M2hOUFBNQk9nVnRoT3NBZDFxNHdSYkxJUEZsM280NlFyRDJlc3JjR3dIbjhtSXZHUHlxNlNwUU1DNTg5Q01pdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-19T11:12:53+00:00", "published_display": "19 May 2024 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Limited (IMRN) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE03bUNjdGlwZWFyYnNPUHA2YTFOM3d6OHhzOW1vOTlQb1gtY0l4d3RVRkpIb2ZIVWRXUElFSUpmQ3RZMlpBLWQ2R0tNTWhzOFVDMkx1Y2UzT3psTFZwdWc4?oc=5", "source_name": "CoinCodex", "published_at": "2023-04-06T12:50:58+00:00", "published_display": "06 Apr 2023 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Stock Price Forecast. Should You Buy IMRN?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE12OVFoZDVrakxxN0pZbGlQaVFTQ3EzalNtZm56Yjc2ZHJKYlZlV0pZWUluT21ZLU1jS2R1VDVMRHpFRjU3SVE4YQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-08T12:28:57+00:00", "published_display": "08 Dec 2020 12:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy IMMURON (IMRN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9iZWhKZlZKQVktcVhTWHBrVW80elNkbklpV2lfbzZ5N0xKNW56dnREaWRWSEpLZWtSc0ZjVE4yb3N2TUJEdTZyMUs2djcxaTVJMXFjU0IzYTFhUzVfN0w4NE0tcXJ2TkM5Z0JTRg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2017-06-14T19:45:54+00:00", "published_display": "14 Jun 2017 19:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPXzBFUW03Sm9pS2YzLWVUeGNRbWR0OEp0Szd6aFZHR2tpWEo5WTlDaEFIUWVzcWkxUGRMYW1SYWV4b1NpRDBnbTVUakFPcFA3QkxONDBENkk5aE52QVlpQlJ4V3czV0s4SDY5TnVfM0VMNGtZMVVZZjhobGg3SUJpS0kzZDJqYW1oZE5JbUFDU3dRdE9kdUhKTEg5MTJWRUg0WnExdEN2T2ZnR2FqdEoxZThraHN1VjVEeXJBTzUwOA?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T15:07:01+00:00", "published_display": "16 Jul 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Reports FY26 Global Sales Up 6% on Strong Travelan Growth in Australia and the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQeEpSVXdrOWdyd3dyVjRQVmhKRzg0R2tyM1NRcHhmOHR2czFVc3JJVWNyRnQ3ZnRjMnkxcnVUV09COEh4Sl9nWUhTVWFvNkJlWDdSMWxPa2tVRkRTM1B4dDVacEFGajlual92NkJITVd0ckJ0ZXhmNEFkdV9aTktibU5taDVqNzVkb2xHU1NxQjY1STlJYnhIN1FRdnZQRjFnb0FHZ09IQTJvR29XWHhBN2htLUhENGhFMkVyS29TMFlVd21T?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T10:11:00+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immuron-fy26-sales-four-consecutive-100000318.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron's Travelan Sales Grow for Four Straight Quarters", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPZDlzUF9pa3kxLXkwMmFsVE9jSVgzcTVPN0lQcXc5UmNtbkR3MExMX0NQRDZfLTAxdmtSaU14VVdHenZLTXkxVUlpd2pIUVRhWjVzM3o4SzhOZ3hFbkNObUNkbDh4RTEtMDdPSDZRdUYwOXpxUG1SRW9MVVhrOGR3NFV6U2J2cV9YS2FlYzNWNGx5VUJ4eG8zV055ZldvZ1kwMkxVRi03cFJzc1JXeE1Id2dHbjV1SGtpNC1FSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia's Immuron sales reach $7.7 million in FY26", "summary": "Immuron (ASX:IMC) announced global sales of $7.7 million for FY26, marking a 6% increase over the previous year. This growth was primarily driven by strong sales of Travelan in Australia and steady expansion in North America. Despite the positive sales figures, the Immuron share ", "url": "https://grafa.com/en/news/australia/immuron-sales-reach-7-7-million-in-fy26", "source_name": "grafa.com", "published_at": "2026-07-16T02:30:00", "published_display": "16 Jul 2026 02:30", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Seeking Partner to Advance IMM-529 in Clostridioides Difficile Infection", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immuron-seeking-partner-advance-imm-110149084.html", "source_name": "MT Newswires", "published_at": "2026-07-06T11:01:49+00:00", "published_display": "06 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push", "summary": "Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for its IMM-529 program, which targets Clostridioides difficile infection (CDI). IMM-529 has FDA Investigational New Drug approval for a planned Phase 2 trial in Australia, with a projected base case ", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-4f81c9b388b4.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:40:42", "published_display": "06 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy", "summary": "Immuron Limited has engaged Pullan Consulting to strategically advance its investigational drug, IMM-529, designed to treat Clostridioides difficile infection (CDI). This move follows the FDA's approval of IMM-529's Investigational New Drug (IND) application, allowing for upcomin", "url": "https://kalkine.com.au/news/announcements/immuron-engages-pullan-consulting-to-advance-imm-529-partnering-strategy", "source_name": "Kalkine", "published_at": "2026-07-06T10:53:00", "published_display": "06 Jul 2026 10:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy", "summary": "Immuron Limited has engaged Pullan Consulting to advance its partnering strategy for IMM-529, a treatment for Clostridioides difficile infection (CDI). The company has FDA approval for its IMM-529 Investigational New Drug application and is seeking a partner to fund clinical deve", "url": "https://markets.businessinsider.com/news/stocks/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-1036299126", "source_name": "markets.businessinsider.com", "published_at": "2026-07-06T10:40:42", "published_display": "06 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron seeks partner for gut infection drug IMM-529", "summary": "Immuron (NASDAQ: IMRN, ASX: IMC) has engaged Pullan Consulting to find a strategic partner for IMM-529, its oral polyclonal antibody candidate for Clostridioides difficile infection (CDI). IMM-529 has FDA-cleared IND 32095 and is Phase 2 trial-ready, with a planned randomized, do", "url": "https://www.stocktitan.net/news/IMRN/immuron-advances-imm-529-clostridioides-difficile-infection-xhzmrjcwvm6o.html", "source_name": "Stock Titan", "published_at": "2026-07-06T09:40:42", "published_display": "06 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) Edges Higher Amid Low-Volume Trading; Potential Consolidation Near Support - ADD Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNZ0xzM0QwQlFCOHpzM1ZuNjFIRnk4bnFtdTNiMDJEU0M1WVFJLUtpcTQtb0ZoNmQ4SlBWNmZtWEhUeWt2NzZSS2hpVkZSSEQySGIzVi02LU9aWmZPVVZMTjlPZllQclIteGRVM21BVWJSTDBlWmt6NEVoUVJlUUlycDRuTGtyQ2pmRGlmc0tjRXpUVHdlNDRZVUQ1cHZRUDg3SmZzU3ZzSzlObTlUNDZBemREVF9wSHd6TzZQM0VIamNESlk5Z3NjcQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T02:31:45+00:00", "published_display": "06 Jul 2026 02:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue", "summary": "Immuron Limited (NASDAQ: IMRN) has announced a change in its issued capital, with 3,805,528 ordinary fully paid shares ceasing on the ASX. Following this cessation, the company now has 322,848,081 ordinary shares on issue. This adjustment to the share count will be used by the AS", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-8e2006592d7c.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:59:39", "published_display": "29 Jun 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Cancels 3.8 Million Shares at $0.032 Each Under Unmarketable Parcel Buy-Back", "summary": "Immuron Limited (ASX: IMC) has completed the cancellation of 3,805,528 ordinary fully paid shares at AUD $0.032 each as part of an unmarketable parcel buy-back program, effective June 29, 2026. This move reduces the company's total quoted ordinary share count to 322,848,081 and a", "url": "https://kalkine.com.au/news/announcements/immuron-cancels-38-million-shares-at-0032-each-under-unmarketable-parcel-buy-back", "source_name": "Kalkine", "published_at": "2026-06-29T02:41:39", "published_display": "29 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Immuron Ltd ADR For: 23 June By Investing.com", "summary": "This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23rd. The content itself is very brief, consisting only of the headline repeated several times, and primarily serves as an entry point to Investing.com's broader financial news and market data platform, wit", "url": "https://in.investing.com/news/stock-market-news/form-6k-immuron-ltd-adr-for-23-june-93CH-5465962", "source_name": "Investing.com India", "published_at": "2026-06-27T04:40:44", "published_display": "27 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Immuron Ltd ADR For: 23 June", "summary": "This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23. It also includes standard disclaimers about the risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility and potential loss of investment. The content stresse", "url": "https://m.uk.investing.com/news/stock-market-news/form-6k-immuron-ltd-adr-for-23-june-93CH-4739689?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T13:10:43", "published_display": "23 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back", "summary": "Immuron Limited has completed a small holding share sale facility, buying back 3,805,528 ordinary shares at $0.032 per share, totaling $121,777. These shares will be cancelled, reducing the company's total shares on issue from 326,653,609 to 322,848,081 and decreasing the number ", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-4c342aaa3c33.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:39:57", "published_display": "22 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital", "summary": "Immuron Limited announced the expiry of 1.43 million IMCAI options listed on the ASX, which ceased on June 18, 2026, without being exercised or converted, and with no consideration paid. Following this, the company updated its issued capital to 326,653,609 ordinary fully paid sha", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-6b8b572858f1.html", "source_name": "Stock Titan", "published_at": "2026-06-19T21:40:54", "published_display": "19 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Immuron Ltd (IMRN). It lists specific institutional shareholders, their shareholdings, and the percentage change in their positions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:23", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Immuron Ltd (IMRN), detailing support and resistance levels, and analyzing various technical indicators and moving averages. As of the report, IMRN's technical indicators present a mixed signal with 1 buy and 2 sell signals, while mov", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:43", "published_display": "17 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Immuron Ltd (IMRN), highlighting that one analyst rates the stock as a \"Buy\" with a target price of USD 5.00, representing a potential upside of 257.14%. The company's current stock price is 1.040 USD, with a market cap of 7.56M. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T07:40:59", "published_display": "17 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immuron Ltd (IMRN)'s dividend and stock split history. It indicates that no dividends have been distributed in the past five years and there is no data available for past stock splits. The page serves as a data placeholder for these financial ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T05:11:30", "published_display": "17 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Immuron Ltd (IMRN), listing its major shareholders and institutional holdings as of recent reporting periods. Key institutional investors include Morgan Stanley, Citadel Advisors, and XTX Markets, with updated statistics on shares", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T05:11:29", "published_display": "17 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd (IMRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Immuron Ltd (IMRN) as of July 6, 2023, showcasing its performance across different business segments and geographical regions. It highlights that the Travelan segment accounts for the vast majority of its revenue at 96.68%, w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T04:11:29", "published_display": "17 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (ASX: IMC): Advancing Gastrointestinal Product Portfolio Across Multiple Markets", "summary": "Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is actively expanding its gastrointestinal product portfolio and market presence, focusing on digestive health with products like Travelan\u00ae for travellers' diarrhoea and ProIBS\u00ae for IBS symptoms. The company reported a 16% increase in globa", "url": "https://kalkinemedia.com/au/news/featured-news/immuron-asx-imc-advancing-gastrointestinal-product-portfolio-across-multiple-markets", "source_name": "Kalkine Media", "published_at": "2026-06-02T04:09:38", "published_display": "02 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRN - Immuron Limited ADR Stock Price and Quote", "summary": "This article provides a detailed stock quote and company information for Immuron Limited (IMRN), an Australian biopharmaceutical company. It includes financial data, performance metrics, key ratios, and a comprehensive list of recent company news and events. The company focuses o", "url": "https://finviz.com/stock?t=IMRN", "source_name": "Finviz", "published_at": "2026-05-30T13:12:29", "published_display": "30 May 2026 13:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (NASDAQ: IMRN) responds to ASX query on share price", "summary": "Immuron Limited has filed a Form 6-K in response to an ASX price query regarding recent trading activity in its shares. The company stated it is not aware of any undisclosed information that would explain the movements and confirmed its compliance with ASX Listing Rule 3.1 on con", "url": "https://www.stocktitan.net/sec-filings/IMRN/6-k-immuron-ltd-current-report-foreign-issuer-4890cba04b2e.html", "source_name": "Stock Titan", "published_at": "2026-05-28T12:08:59", "published_display": "28 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRN Technical Analysis | Trend, Signals & Chart Patterns | IMMURON LTD-SPON ADR (NASDAQ:IMRN)", "summary": "IMMURON LTD-SPON ADR (IMRN) has a strong technical rating of 8 out of 10, showing positive short-term trends and outperforming 85% of all stocks in the past year. However, its setup rating is low at 1 due to extended recent price rises, suggesting a wait for consolidation before ", "url": "https://www.chartmill.com/stock/quote/IMRN/technical-analysis", "source_name": "ChartMill", "published_at": "2026-05-27T11:39:03", "published_display": "27 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00", "summary": "Emerging Growth Research has released a Flash Report on Immuron (Nasdaq: IMRN), reaffirming its Buy-Extended rating and elevating its 12-month price target from $3.90 to $4.00. This increase reflects Immuron's continued revenue growth, expanding commercial presence, and advanceme", "url": "https://www.moomoo.com/news/post/68690949/emerging-growth-research-releases-flash-report-on-immuron-maintains-buy", "source_name": "Moomoo", "published_at": "2026-05-23T10:40:17", "published_display": "23 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3", "summary": "Immuron Ltd Chief Commercial Officer Flavio Palumbo has filed an initial ownership report (Form 3) disclosing his equity interests in the company. The filing indicates he directly holds 1,142,909 Ordinary Shares and 640,824 Performance Rights. These Performance Rights have a zero", "url": "https://www.stocktitan.net/sec-filings/IMRN/form-3-immuron-ltd-initial-statement-of-beneficial-ownership-7272ca8cfdf2.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:10:11", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) director discloses shareholdings and long-dated options", "summary": "Immuron Ltd director Daniel Jude Pollock has filed an initial Form 3, disclosing his direct ownership of 568,750 Ordinary Shares and indirect ownership of 174,480 Ordinary Shares through joint ownership with his spouse. The filing also reveals his holdings of options over 1,000,0", "url": "https://www.stocktitan.net/sec-filings/IMRN/form-3-immuron-ltd-initial-statement-of-beneficial-ownership-74f4d58890a1.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:10:11", "published_display": "14 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Ltd IMRN", "summary": "This page provides an overview of Immuron Ltd (IMRN) stock, showing its current trading price, market capitalization, and recent performance. The stock is trading at $0.880, up 9.86%, with a market cap of $5.15M. The page includes sections for financials, discussions, and analysi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imrn/comments", "source_name": "TradingKey", "published_at": "2026-05-13T08:39:17", "published_display": "13 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) Sees Impressive Sales Surge for Travelan in FY25", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQbjMxZEVCbnltUFhvUEtmd2g1RkUtaEpPaktVWTFkUXJoXy03SWdrcUVJOTdWZDJWcVNWbTdCMXA5bTAyanMzTWxIemNzX3d6R2NBRndNRUVqSWtBVWZaOG5obTBXd0E5RU5pajdTeU1iMHhHcGxJN1gyM0FqUU83azZvWXJURFktVkVJYzlVNHFqMUhQUlZZeTVZd2VNdXNiNXg2dDFqakIwbl85anJtc1dhRTZpNnBRMGkyaTlVVXNiZ0JNTFhj?oc=5", "source_name": "GuruFocus", "published_at": "2025-07-17T07:00:00+00:00", "published_display": "17 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron (IMRN) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5VQkRiNXRSbmkyTkVWQzNsbjJuQkhlOFBfWkt5RHR5M2hOUFBNQk9nVnRoT3NBZDFxNHdSYkxJUEZsM280NlFyRDJlc3JjR3dIbjhtSXZHUHlxNlNwUU1DNTg5Q01pdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-19T11:12:53+00:00", "published_display": "19 May 2024 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Limited (IMRN) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE03bUNjdGlwZWFyYnNPUHA2YTFOM3d6OHhzOW1vOTlQb1gtY0l4d3RVRkpIb2ZIVWRXUElFSUpmQ3RZMlpBLWQ2R0tNTWhzOFVDMkx1Y2UzT3psTFZwdWc4?oc=5", "source_name": "CoinCodex", "published_at": "2023-04-06T12:50:58+00:00", "published_display": "06 Apr 2023 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuron Stock Price Forecast. Should You Buy IMRN?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE12OVFoZDVrakxxN0pZbGlQaVFTQ3EzalNtZm56Yjc2ZHJKYlZlV0pZWUluT21ZLU1jS2R1VDVMRHpFRjU3SVE4YQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-08T12:28:57+00:00", "published_display": "08 Dec 2020 12:28", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy IMMURON (IMRN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9iZWhKZlZKQVktcVhTWHBrVW80elNkbklpV2lfbzZ5N0xKNW56dnREaWRWSEpLZWtSc0ZjVE4yb3N2TUJEdTZyMUs2djcxaTVJMXFjU0IzYTFhUzVfN0w4NE0tcXJ2TkM5Z0JTRg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2017-06-14T19:45:54+00:00", "published_display": "14 Jun 2017 19:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 81, "total_relevant": 44, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 25, "score": 56, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.23, "latest_week": "2026-07-10", "one_week_move": 11.8, "four_week_move": 3.4, "twelve_week_move": 28.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.84506, "market_dynamics_buy_signal": false, "relative_strength": -19.780272, "fair_value_gap": -32.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.6576, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+11.8% over one week, +3.4% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 5}, {"label": "Kalkine", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Quiver Quantitative", "count": 1}, {"label": "GlobeNewswire", "count": 1}, {"label": "grafa.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 10}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+11.8% over one week, +3.4% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits"}], "updated_at": "2026-07-16T15:23:17.461884+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}